Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company`s lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn`s disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Website: ventyxbio.com




Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -93.6% (LTM)

Entry Point: Share price is 106.8% higher than minimum and 91.6% lower than maximum for the last 3 years

Insiders: For the last 3 months insiders sold company shares on $0.0 mln (-0.017% of cap.)

Key Financials (Download financials)

Ticker: VTYX
Share price, USD:  (-3.2%)3.93
year average price 18.47  


year start price 39.15 2023-05-01

max close price 40.30 2023-07-03

min close price 1.90 2024-01-18

current price 3.93 2024-04-29
Common stocks: 52 471 003

Dividend Yield:  0.0%
Last revenue growth (y/y):  ---
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 206
Net Debt ($m): -40
EV (Enterprise Value): 166
Price to Book: 0.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-11-09Zacks Investment Research

Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a Turnaround

2023-11-07Seeking Alpha

Ventyx Biosciences Now Has 2 Strikes

2023-11-07InvestorPlace

Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today?

2023-11-07Market Watch

Ventyx Biosciences' stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target

2023-10-11Zacks Investment Research

Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data

2023-10-10The Motley Fool

Why Shares of Ventyx Biosciences Are Dropping Tuesday

2023-08-13Seeking Alpha

Ventyx Biosciences, Inc. (VTYX) Q2 2023 Earnings Call Transcript

2023-07-03The Motley Fool

Why Shares of Ventyx Biosciences Rose Monday

2023-06-15Seeking Alpha

Ventyx: Critical Proof Of Concept Data Later This Year

2023-05-14Seeking Alpha

Ventyx Biosciences, Inc. (VTYX) Q1 2023 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VTYX VTYX VTYX VTYX VTYX VTYX
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-27 2023-11-09 2023-08-10 2023-05-11 2023-03-23 2022-11-04
acceptedDate 2024-02-27 16:15:34 2023-11-09 16:20:33 2023-08-10 16:16:55 2023-05-11 16:21:17 2023-03-23 16:17:35 2022-11-04 17:28:42
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 0 0 0 0 0
costOfRevenue 403 000 265 000 139 000 0 0 0
grossProfit -403 000 -265 000 -139 000 0 0 0
grossProfitRatio 0 0 0 0 0 0
researchAndDevelopmentExpenses 40M 50M 49M 35M 30M 25M
generalAndAdministrativeExpenses 8M 8M 9M 7M 8M 6M
sellingAndMarketingExpenses -903 000 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 7M 8M 9M 7M 8M 6M
otherExpenses -28 000 -8000.000 -5000.000 -1000.000 172 000 0
operatingExpenses 48M 58M 57M 43M 39M 31M
costAndExpenses 48M 58M 57M 43M 39M 31M
interestIncome 4M -4M 4M 4M 3M 0
interestExpense 0 0 0 -4M -3M -958 000
depreciationAndAmortization 403 000 265 000 139 000 134 000 3M 1M
ebitda -48M -58M -57M -43M -35M -30M
ebitdaratio 0 0 0 0 0 0
operatingIncome -48M -58M -57M -43M -39M -31M
operatingIncomeRatio 0 0 0 0 0 0
totalOtherIncomeExpensesNet 1M 4M -5000.000 4M 3M 958 000
incomeBeforeTax -47M -54M -53M -39M -35M -30M
incomeBeforeTaxRatio 0 0 0 0 0 0
incomeTaxExpense 0 -265 000 -4M -4M -150 000 -958 000
netIncome -47M -54M -53M -35M -35M -30M
netIncomeRatio 0 0 0 0 0 0
eps -0.790 -0.920 -0.910 -0.610 -0.620 -0.570
epsdiluted -0.790 -0.920 -0.910 -0.610 -0.620 -0.570
weightedAverageShsOut 59M 59M 59M 58M 57M 52M
weightedAverageShsOutDil 59M 59M 59M 58M 57M 52M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VTYX VTYX VTYX VTYX VTYX VTYX
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-27 2023-11-09 2023-08-10 2023-05-11 2023-03-23 2022-11-04
acceptedDate 2024-02-27 16:15:34 2023-11-09 16:20:33 2023-08-10 16:16:55 2023-05-11 16:21:17 2023-03-23 16:17:35 2022-11-04 17:28:42
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 52M 57M 52M 64M 65M 263M
shortTermInvestments 201M 244M 281M 313M 253M 149M
cashAndShortTermInvestments 252M 301M 332M 377M 357M 412M
netReceivables 800 000 0 0 49 000 0 0
inventory -800 000 0 0 0 0 0
otherCurrentAssets 12M 7M 14M 10M 13M 6M
totalCurrentAssets 264M 308M 347M 387M 331M 418M
propertyPlantEquipmentNet 12M 13M 2M 2M 2M 2M
goodwill 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets -3M 0 0 0 0 0
longTermInvestments 975 000 975 000 0 0 39M 0
taxAssets 2M 0 0 0 0 0
otherNonCurrentAssets 1M 102 000 102 000 96 000 96 000 72 000
totalNonCurrentAssets 13M 14M 2M 2M 41M 2M
otherAssets 0.000 -0.000 0.000 0 0 0
totalAssets 278M 322M 349M 389M 371M 420M
accountPayables 6M 9M 4M 7M 6M 19M
shortTermDebt 1M 479 000 439 000 426 000 412 000 395 000
taxPayables 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0
otherCurrentLiabilities 16M 16M 16M 10M 10M 17M
totalCurrentLiabilities 22M 26M 20M 17M 16M 36M
longTermDebt 12M 12M 922 000 1M 1M 1M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 2M 0 0 0 0 0
otherNonCurrentLiabilities -2M 0 0 0 0 -18M
totalNonCurrentLiabilities 12M 12M 922 000 1M 1M 1M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 13M 12M 1M 1M 2M 2M
totalLiabilities 34M 38M 21M 18M 18M 37M
preferredStock 0 0 0 0 0 0
commonStock 6000.000 6000.000 6000.000 6000.000 6000.000 6000.000
retainedEarnings -419M -372M -318M -265M -226M -191M
accumulatedOtherComprehensiveIncomeLoss -50 000 -507 000 -710 000 -561 000 -1M -1M
othertotalStockholdersEquity 663M 657M 647M 555 000 1M 576M
totalStockholdersEquity 244M 284M 328M -265M -226M 384M
totalEquity 244M 284M 328M -265M -226M 384M
totalLiabilitiesAndStockholdersEquity 278M 322M 349M -248M -209M 420M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 278M 322M 349M -248M -209M 420M
totalInvestments 201M 244M 281M 313M 292M 149M
totalDebt 13M 12M 1M 1M 2M 2M
netDebt -39M -44M -50M -62M -63M -262M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VTYX VTYX VTYX VTYX VTYX VTYX
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-27 2023-11-09 2023-08-10 2023-05-11 2023-03-23 2022-11-04
acceptedDate 2024-02-27 16:15:34 2023-11-09 16:20:33 2023-08-10 16:16:55 2023-05-11 16:21:17 2023-03-23 16:17:35 2022-11-04 17:28:42
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -47M -54M -53M -39M -35M -30M
depreciationAndAmortization 403 000 265 000 139 000 134 000 150 000 127 000
deferredIncomeTax -11M 0 0 0 0 0
stockBasedCompensation 6M 8M 8M 7M 5M 4M
changeInWorkingCapital -9M 13M -2M 3M -15M 3M
accountsReceivables 0 0 0 0 0 0
inventory 0 0 0 0 0 0
accountsPayables -4M 5M -2M -91 000 -8M 9M
otherWorkingCapital -6M 8M 733 000 91 000 -7M -6M
otherNonCashItems 8M -2M -2M -2M -2M -386 000
netCashProvidedByOperatingActivities -52M -35M -49M -31M -47M -24M
investmentsInPropertyPlantAndEquipment -211 000 -48 000 -195 000 -60 000 -112 000 -97 000
acquisitionsNet -46 336 -38 939 -35 014 0 1M 0
purchasesOfInvestments -29M -71M -64M -109M -205M -17M
salesMaturitiesOfInvestments 75M 110M 99M 90M 64M 81M
otherInvestingActivites 46 336 38 939 35 014 0 -1M 0
netCashUsedForInvestingActivites 46M 39M 35M -19M -141M 64M
debtRepayment 0 0 0 0 0 0
commonStockIssued 585 000 2M -47 000 48M -11M 0
commonStockRepurchased 0 0 0 0 267 000 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 585.000 -78 000 3M 191 000 510 000 178M
netCashUsedProvidedByFinancingActivities 585 000 2M 2M 49M -10M 178M
effectOfForexChangesOnCash -86 000 16 000 38 000 20 000 8000.000 -38 000
netChangeInCash -5M 6M -12M -1M -198M 218M
cashAtEndOfPeriod 52M 58M 52M 64M 65M 263M
cashAtBeginningOfPeriod 57M 52M 64M 65M 263M 45M
operatingCashFlow -52M -35M -49M -31M -47M -24M
capitalExpenditure -211 000 -48 000 -195 000 -60 000 -112 000 -97 000
freeCashFlow -52M -35M -49M -31M -47M -24M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q2
2023-08-13 ET (fiscal 2023 q2)
2023 q1
2023-05-14 ET (fiscal 2023 q1)
2022 q4
2023-03-23 ET (fiscal 2022 q4)
2022 q3
2022-11-06 ET (fiscal 2022 q3)
2022 q2
2022-08-16 ET (fiscal 2022 q2)
2022 q1
2022-05-13 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-27 21:01 ET
Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress
2024-02-22 12:00 ET
Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)
2024-02-06 21:05 ET
Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2023-11-21 21:05 ET
Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference
2023-11-10 13:00 ET
Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference
2023-11-09 21:01 ET
Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress
2023-11-06 21:01 ET
Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update
2023-10-09 20:01 ET
Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis
2023-08-30 20:05 ET
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
2023-08-10 20:01 ET
Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress
2023-08-03 20:05 ET
Ventyx Biosciences to Report Second Quarter 2023 Financial Results on August 10, 2023
2023-08-02 20:06 ET
Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference
2023-06-14 11:00 ET
Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
2023-06-07 11:00 ET
Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis
2023-05-31 12:00 ET
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
2023-05-11 20:01 ET
Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
2023-05-04 20:05 ET
Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023
2023-03-24 12:00 ET
Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
2023-03-23 20:01 ET
Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress
2023-03-15 20:05 ET
Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
2023-03-11 18:21 ET
Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure
2023-02-28 13:00 ET
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
2023-01-26 13:00 ET
Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day
2023-01-12 13:00 ET
Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors
2023-01-05 13:00 ET
Ventyx Biosciences to Host R&D Event on January 26, 2023
2022-12-01 21:05 ET
Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis
2022-11-22 13:00 ET
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
2022-11-03 20:01 ET
Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
2022-10-27 20:05 ET
Ventyx Biosciences to Report Third Quarter 2022 Financial Results on November 3, 2022
2022-10-27 13:00 ET
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
2022-09-19 12:00 ET
Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock
2022-08-29 20:05 ET
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
2022-08-15 20:05 ET
Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
2022-08-15 20:01 ET
Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958
2022-08-11 20:05 ET
Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK 2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022
2022-06-29 12:00 ET
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735
2022-06-01 12:00 ET
Ventyx Biosciences to Participate in the Jefferies Healthcare Conference
2022-05-12 20:01 ET
Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
2022-05-09 12:00 ET
Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer
2022-05-05 20:05 ET
Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022
2022-03-23 12:00 ET
Ventyx Biosciences Reports Full Year 2021 Financial Results and Highlights Recent Corporate Progress
2022-03-07 13:00 ET
Ventyx Biosciences to Participate in the Barclays Global Healthcare Conference
2021-12-06 13:00 ET
Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis
2021-11-19 13:00 ET
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
2021-11-17 21:11 ET
Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update
2021-10-25 20:58 ET
Ventyx Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SEC forms

Show financial reports only

SEC form 10
2024-02-27 16:15 ET
Ventyx Biosciences, Inc. reported for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Ventyx Biosciences, Inc. reported for 2023 q4
SEC form 8
2024-02-27 00:00 ET
Ventyx Biosciences, Inc. published news for 2023 q4
SEC form 8
2024-02-27 00:00 ET
Ventyx Biosciences, Inc. published news for 2023 q4
SEC form 10
2023-11-09 16:20 ET
Ventyx Biosciences, Inc. reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Ventyx Biosciences, Inc. reported for 2023 q3
SEC form 8
2023-11-09 00:00 ET
Ventyx Biosciences, Inc. published news for 2023 q3
SEC form 8
2023-11-06 00:00 ET
Ventyx Biosciences, Inc. published news for 2023 q3
SEC form 10
2023-08-10 16:16 ET
Ventyx Biosciences, Inc. reported for 2023 q2
SEC form 6
2023-08-10 16:07 ET
Ventyx Biosciences, Inc. reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Ventyx Biosciences, Inc. reported for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Ventyx Biosciences, Inc. reported for 2023 q2
SEC form 6
2023-07-25 18:58 ET
Ventyx Biosciences, Inc. published news for 2023 q2
SEC form 10
2023-05-11 16:21 ET
Ventyx Biosciences, Inc. reported for 2023 q1
SEC form 6
2023-05-11 16:07 ET
Ventyx Biosciences, Inc. reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Ventyx Biosciences, Inc. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Ventyx Biosciences, Inc. reported for 2023 q1
SEC form 6
2023-04-26 16:16 ET
Ventyx Biosciences, Inc. published news for 2023 q1
SEC form 6
2023-04-13 17:45 ET
Ventyx Biosciences, Inc. published news for 2023 q1
SEC form 10
2023-03-23 16:17 ET
Ventyx Biosciences, Inc. reported for 2022 q4
SEC form 6
2023-03-23 16:05 ET
Ventyx Biosciences, Inc. reported for 2022 q4
SEC form 8
2023-03-23 00:00 ET
Ventyx Biosciences, Inc. reported for 2022 q4
SEC form 10
2023-03-23 00:00 ET
Ventyx Biosciences, Inc. reported for 2022 q4
SEC form 6
2023-01-26 16:07 ET
Ventyx Biosciences, Inc. published news for 2022 q4
SEC form 6
2023-01-12 17:09 ET
Ventyx Biosciences, Inc. published news for 2022 q4
SEC form 6
2023-01-12 17:01 ET
Ventyx Biosciences, Inc. published news for 2022 q4
SEC form 6
2023-01-12 16:05 ET
Ventyx Biosciences, Inc. published news for 2022 q4
SEC form 6
2022-12-20 16:54 ET
Ventyx Biosciences, Inc. published news for 2022 q3
SEC form 6
2022-12-12 17:00 ET
Ventyx Biosciences, Inc. published news for 2022 q3
SEC form 6
2022-11-30 16:37 ET
Ventyx Biosciences, Inc. published news for 2022 q3
SEC form 10
2022-11-04 17:28 ET
Ventyx Biosciences, Inc. reported for 2022 q3
SEC form 10
2022-11-04 00:00 ET
Ventyx Biosciences, Inc. reported for 2022 q3
SEC form 6
2022-11-03 16:10 ET
Ventyx Biosciences, Inc. reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Ventyx Biosciences, Inc. reported for 2022 q3
SEC form 6
2022-09-19 08:10 ET
Ventyx Biosciences, Inc. published news for 2022 q2
SEC form 10
2022-08-15 16:46 ET
Ventyx Biosciences, Inc. reported for 2022 q2
SEC form 6
2022-08-15 16:32 ET
Ventyx Biosciences, Inc. reported for 2022 q2
SEC form 8
2022-08-15 00:00 ET
Ventyx Biosciences, Inc. reported for 2022 q2
SEC form 10
2022-08-15 00:00 ET
Ventyx Biosciences, Inc. reported for 2022 q2
SEC form 6
2022-06-29 08:30 ET
Ventyx Biosciences, Inc. published news for 2022 q1
SEC form 6
2022-06-09 16:37 ET
Ventyx Biosciences, Inc. published news for 2022 q1
SEC form 10
2022-05-12 16:28 ET
Ventyx Biosciences, Inc. reported for 2022 q1
SEC form 6
2022-05-12 16:09 ET
Ventyx Biosciences, Inc. published news for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Ventyx Biosciences, Inc. reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Ventyx Biosciences, Inc. reported for 2022 q1
SEC form 6
2022-05-09 08:23 ET
Ventyx Biosciences, Inc. published news for 2022 q1
SEC form 6
2022-05-09 08:07 ET
Ventyx Biosciences, Inc. published news for 2022 q1
SEC form 6
2022-04-27 16:10 ET
Ventyx Biosciences, Inc. published news for 2022 q1
SEC form 10
2022-03-24 00:00 ET
Ventyx Biosciences, Inc. published news for 2021 q4
SEC form 10
2022-03-23 17:49 ET
Ventyx Biosciences, Inc. published news for 2021 q4
SEC form 6
2022-03-23 08:15 ET
Ventyx Biosciences, Inc. published news for 2021 q4
SEC form 8
2022-03-23 00:00 ET
Ventyx Biosciences, Inc. published news for 2021 q4
SEC form 6
2022-03-15 06:07 ET
Ventyx Biosciences, Inc. published news for 2021 q4
SEC form 6
2021-11-30 16:06 ET
Ventyx Biosciences, Inc. published news for 2021 q3
SEC form 10
2021-11-18 00:00 ET
Ventyx Biosciences, Inc. published news for 2021 q3
SEC form 10
2021-11-17 20:35 ET
Ventyx Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-11-17 16:23 ET
Ventyx Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-10-25 17:09 ET
Ventyx Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-10-20 18:53 ET
Ventyx Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-10-20 18:50 ET
Ventyx Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-10-20 18:48 ET
Ventyx Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-10-20 18:48 ET
Ventyx Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-10-20 18:47 ET
Ventyx Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-10-20 18:47 ET
Ventyx Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-10-20 18:45 ET
Ventyx Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-10-20 18:44 ET
Ventyx Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-10-20 18:43 ET
Ventyx Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-10-20 18:42 ET
Ventyx Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-10-20 18:41 ET
Ventyx Biosciences, Inc. published news for 2021 q3